{
    "nctId": "NCT00099008",
    "briefTitle": "Genistein in Preventing Breast or Endometrial Cancer in Healthy Postmenopausal Women",
    "officialTitle": "Phase I Multiple Dose Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Endometrial Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Efficacy of genistein on DNA and apoptosis",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Healthy participants\n\n  * Papanicolaou test (pap smear) normal within the past 13 months\n  * Mammogram normal within the past 13 months\n* No history of breast cancer\n* Not at high-risk (5-year risk \\< 1.9%) for breast cancer according to NCI's Breast Cancer Risk Assessment Tool\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n* 45 to 70\n\nSex\n\n* Female\n\nMenopausal status\n\n* Postmenopausal\n\n  * Last spontaneous menstrual bleeding \\> 12 months ago\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* WBC \u2265 3,500/mm\\^3\n* Platelet count \u2265 100,000/mm\\^3\n\nHepatic\n\n* Bilirubin \u2264 2.0 mg/dL\n* ALT and AST \\< 2 times normal\n* No significant abnormality of the liver by physical exam\n\nRenal\n\n* Creatinine \\< 2.0 mg/dL\n\nCardiovascular\n\n* No significant cardiac disease\n* No New York Heart Association class III or IV heart disease\n* No significant abnormality of the heart by physical exam\n\nPulmonary\n\n* No significant abnormality of the lung by physical exam\n\nOther\n\n* Body mass index \\< 35\n* Follicle-stimulating hormone \\> 27 mIU/mL\n* Thyroid or endocrine function test normal\n* Alcohol intake \u2264 2 drinks/day or \u226414 drinks/week\n* Not pregnant\n* No intermediate equol values (\u226510 ug/L to \u2264 20 ug/L) on soy challenge\n* No history of seizures\n* No significant abnormality of the spleen or other abdominal organs by physical exam\n* No neurologic abnormality by physical exam\n* No significant metabolic abnormality on the biochemical screen\n* No history of substance abuse or addiction\n* No tobacco use\n* No diets containing \\> 20 mg of genistein/day or \\> 40 mg isoflavone/day\n* No known intolerance to soy\n* No other serious medical illness\n* No active malignancy or malignancy initially diagnosed within the past 2 years except curatively treated nonmelanoma skin cancer\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* More than 2 years since prior chemotherapy\n* No concurrent chemotherapy\n\nEndocrine therapy\n\n* More than 3 months since prior hormonal or estrogen therapy\n* More than 3 months since prior tamoxifen or other selective estrogen-receptor modulators\n* More than 1 month since prior supplements containing phytoestrogens or that have estrogenic side effects (soy isoflavones or PC-SPECS)\n* No concurrent thyroid medication\n\n  * Other concurrent endocrine medication allowed provided medication was initiated \u2265 3 months before study entry AND participant has been on a stable regimen for the past 3 months\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* No prior hysterectomy or oophorectomy\n\nOther\n\n* More than 3 months since prior antibiotics",
    "sex": "FEMALE",
    "minimumAge": "45 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}